Heterologous immunity to Epstein-Barr virus: dissecting the role of cross-reactive CD8 T cells in mediating disease outcome in children, young adults and the elderly

Informazioni relative al progetto

EBV HORIZONS

ID dell’accordo di sovvenzione: 219603

Progetto chiuso

Data di avvio 1 Maggio 2008

Data di completamento 30 Aprile 2011

Finanziato da

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Costo totale € 240 373,81

Contributo UE € 240 373,81

Coordinato da

CARDIFF UNIVERSITY
United Kingdom